The National Institute for Biological Standards and Control (NIBSC) is one of 26 organisations promoting innovative vaccine research and development through the new European Commission (EC)-funded initiative TRANSVAC2.
The project, which began in May 2017, will encourage collaboration within the European vaccine community to accelerate development of safe, effective and affordable vaccines.
About the project
TRANSVAC2 will support innovation for both prophylactic and therapeutic vaccine development.
Based on a disease-overarching ‘One Health’ approach, the project will combine knowledge and expertise gained from research into both human and animal vaccines to provide a universal framework for vaccine development.
It aims to support the translation of biomedical research into effective vaccines by encouraging cooperation between public vaccine R&D institutions of excellence, industrial partners and related European initiatives, and providing transnational access to services aimed at accelerating the development of experimental vaccines.
This five-year initiative follows on from the successful TRANSVAC project, funded under the EC´s previous Framework Programme (FP7), that helped advance more than 29 vaccine studies through the provision of resources and training, data and scientific expertise.
TRANSVAC2 has received funds from the European Commission’s Horizon2020 programme and is co-ordinated by the European Vaccine Initiative (EVI).
Helping to deliver effective vaccines
Dr Odile Leroy, Executive Director of the EVI and coordinator of TRANSVAC2 said:
“The TRANSVAC2 activities will further strengthen the vaccine R&D infrastructure in Europe and accelerate the development of effective vaccines that are urgently needed to address global health challenges”
Dr Mei Mei Ho from the Division of Bacteriology at NIBSC, adds:
"With our experience NIBSC will contribute to several key activities, including assay development, and provide our scientific and technical expertise through networking opportunities."
For more information on TRANSVAC2 visit the European Vaccine Initiative’s website.